Geeta Upadhyay, PhD
Geeta Upadhyay, PhD
Name: Geeta Upadhyay, PhD
Drug-protein interaction, tumor model
MS (1996), Organic Chemistry, Lucknow University, Lucknow, India,
PhD (2003), Breast Cancer, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India (1997-2000); University of Ulm, Ulm, Germany (2000-2002),
Research Fellow, Neurological Diseases, University of Texas Heath Science Center, San Antonio, TX 2002-2003
Research Fellow, Breast Cancer, National Cancer Institute, Bethesda, MD 2003-2004
Research Fellow, Gastrointestinal Cancer, Harvard Medical School, Boston, MA 2004-2007
Research Fellow, Breast Cancer, Georgetown University, Washington, DC 2007-2011
Dr. Upadhyay received award winning PhD degree in 2003 from Molecular Endocrinology of breast cancer at Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow. Dr. Upadhyay received her postdoctoral training at Harvard Medical School, Boston; National Institute of Health, Bethesda, University of Texas Health Science Center of San Antonio in the areas of breast, colon cancer and cell signaling pathways of Wnt and oxidative stress pathways. Her postdoctoral work led to identification of a novel regulator DOCK4 in non-canonical Wnt pathway. Dr. Upadhyay served as research faculty at Georgetown University, Washington, DC where she made original observation that stem cell maker Sca-1 binds with TGF-beta receptor-1 in order to disrupt TGF-beta signaling.
Representative publications, projects, and/or deployments
- since 2020: Associate Professor on tenure track, Pathology Uniformed Services University of Health Sciences, Bethesda, MD
- 2018 - 2020: Assistant Professor on tenure track, Pathology Uniformed Services University of Health Sciences, Bethesda, MD
- since 2018: Adjunct Associate Professor, Georgetown University Medical Center, Washington, DC
- 2014 - 2018 Assistant Professor, Oncology, Georgetown University Medical Center, Washington, DC
- 2011 - 2014 Assistant Professor, Pathology, Georgetown University Medical Center, Washington, DC
- since 2018: Member, John P Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of Health Science Center
- 2017: Young Investigator Award, Society for Immunotherapy of Cancer, Washington, DC
- 2014: Membership, Early Career Scientific Reviewer, Center for Scientific Review, NIH, Bethesda, MD
- 2011, 2018: Scientific Peer Reviewer (Grants), Breast Cancer Research Program, Department of Defense, CDMRP
- 2015-2018: Scientific Peer Reviewer (Grants), Various Study sections at CSR, NIH
- Upadhyay G, Yin Y, Yuan H, Li X, Derynck R, Glazer RI. Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-beta signaling. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7820-5. PMCID: PMC3093514.
- Luo L, McGarvey P, Madhavan S, Kumar R, Gusev Y, Upadhyay G. Lymphocyte antigens 6 complex gene family members drive tumorigenesis. Oncotarget, 2016 Feb 3, 7(10):11165-93, DOI:10.18632. PMID: 26862846
- AlHossiny M, Luo L, Frazier WR, Steiner N, Gusev Y, Kallakury B, Glasgow E, Creswell K, Madhavan S, Kumar R, Upadhyay G. Lymphocyte antigens 6 complex K/E-transforming growth factor-beta axis promotes breast cancer tumorigenesis. Cancer Research Published Online First April 11, 2016; doi: 10.1158/0008-5472.CAN-15-2654.
- Ligaba SB, Khurana A, Graham G, Krawczyk E, Jablonski S, Petricoin EF, Glazer RI, Upadhyay G. Multifactorial analysis of conditional reprogramming of human keratinocytes. PLoS One. 2015;10(2):e0116755. PMID: 4340869.